NCT06508567 Salvage MR-guided High-Dose-Rate Brachytherapy for Prostate Bed Recurrence After Radiotherapy in the PSMA PET Scan Era
| NCT ID | NCT06508567 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Health Network, Toronto |
| Condition | Prostate Cancer Recurrent |
| Study Type | INTERVENTIONAL |
| Enrollment | 20 participants |
| Start Date | 2024-08-08 |
| Primary Completion | 2026-08-08 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 20 participants in total. It began in 2024-08-08 with a primary completion date of 2026-08-08.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is an interventional, single-centre, single-arm, non-randomized, prospective, feasibility trial investigating salvage MR-guided High-Dose-Rate brachytherapy for prostate bed recurrence after postoperative radiotherapy.
Eligibility Criteria
Inclusion Criteria: 1. Patients who received previous RT to the prostate bed +/- pelvic nodal regions 2. Prostate-bed recurrence identified by biopsy and/or MRI and/or PSMA-PET scan 3. At least two continuous PSA elevations post RT and PSA above 0.2 ng/dl 4. With or without ADT PSA doubling time from nadir greater than 6 months 5. ECOG 0-2 6. Age greater than 18 years Exclusion Criteria: 1. Radiological (e.g. PSMA PET, CT, MRI or bone scan) evidence of or distant metastases 2. History of ≥G3 gastrointestinal (GI) and genitourinary (GU) toxicities following RT 3. Any contraindications to MR and/or brachytherapy
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06508567 clinical trial?
This trial is open to male participants only, aged 18 Years or older, studying Prostate Cancer Recurrent. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06508567 currently recruiting?
Yes, NCT06508567 is actively recruiting participants. Contact the research team at peter.chung@uhn.ca for enrollment information.
Where is the NCT06508567 trial being conducted?
This trial is being conducted at Toronto, Canada.
Who is sponsoring the NCT06508567 clinical trial?
NCT06508567 is sponsored by University Health Network, Toronto. The trial plans to enroll 20 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.